Neck Lumps

Last updated 31 May 2026 · General Practice / ENT

📋 Key Information Summary

📋

Most neck lumps in adults are benign; however, any persistent neck lump in a patient >45 years with risk factors for malignancy warrants urgent ENT referral within 2 weeks.
The 70% rule applies: ~70% of neck lumps in adults are neoplastic, and ~70% of neoplastic neck lumps are malignant — in contrast, >80% of paediatric neck lumps are inflammatory or infectious.
A systematic diagnostic approach uses history (duration, growth rate, associated symptoms), examination (site, size, consistency, mobility, tenderness), and age-based differential diagnosis.
Red-flag features demanding urgent referral include: hard, fixed, non-tender mass; hoarseness, dysphagia, or straddle; unexplained weight loss; age >45 with persistent lump >3 weeks; supraclavicular lymphadenopathy; and history of head and neck cancer or smoking/alcohol excess.
Cervical lymphadenopathy is the most common cause of neck lumps overall — reactive/infective causes predominate in children and young adults; persistent or atypical lymphadenopathy must be biopsied to exclude lymphoma or metastatic squamous cell carcinoma.
A solitary, firm, non-tender, progressively enlarging cervical node is metastatic SCC of the head and neck until proven otherwise, particularly in patients with smoking and alcohol history.
Thyroid nodules and goitre are common midline/lower-neck masses; assess with TSH, free T4, ultrasound ± fine-needle aspiration (FNA) cytology using the Bethesda classification.
Branchial cleft cysts typically present as smooth, fluctuant, lateral neck masses anterior to the sternocleidomastoid; they may become infected and require surgical excision after infection resolution.
Pharyngeal pouch (Zenker's diverticulum) classically presents in elderly patients with dysphagia, regurgitation of undigested food, gurgling sounds, and a reducible left-sided neck mass; diagnosis is by barium swallow; management is endoscopic or open surgical.
Fine-needle aspiration (FNA) cytology is the first-line investigation for most persistent or suspicious neck lumps; it has high sensitivity for thyroid lesions and metastatic SCC; core biopsy or open biopsy may be needed for suspected lymphoma.
Aboriginal and Torres Strait Islander Australians have higher rates of head and neck cancers, delayed presentation, and reduced access to specialist ENT services in remote communities — culturally safe, timely referral pathways are essential.
In endemic regions (Northern Territory, Far North Queensland), consider Mycobacterium ulcerans (Bairnsdale ulcer), non-tuberculous mycobacteria (NTM), and scrofula (tuberculous lymphadenitis) in the differential of chronic cervical lymphadenopathy.

Introduction & Australian Epidemiology

Neck lumps are a common presenting complaint in Australian general practice, accounting for approximately 2–4% of all consultations involving a palpable mass. The differential diagnosis is broad, encompassing congenital, infective/inflammatory, and neoplastic aetiologies. A structured diagnostic approach is essential to avoid unnecessary investigation while ensuring that sinister causes — particularly head and neck malignancy — are identified without delay.

In Australia, head and neck cancers represent the seventh most common cancer group, with approximately 5,200 new diagnoses annually (AIHW, 2023). Squamous cell carcinoma (SCC) of the upper aerodigestive tract accounts for the majority, with lymph node metastasis being the presenting feature in 30–40% of cases. Lymphoma (both Hodgkin and non-Hodgkin) is the second most common neoplastic cause of cervical lymphadenopathy. Thyroid nodules are found in up to 50% of the adult population on ultrasound, though the vast majority are benign.

Infection-related cervical lymphadenopathy remains the most common cause in children and young adults, with upper respiratory tract infections, pharyngitis, dental infections, and Epstein-Barr virus (EBV) being leading aetiologies. In Aboriginal and Torres Strait Islander populations and in tropical northern Australia, additional infectious aetiologies — including tuberculosis, NTM, and skin and soft tissue infections — contribute disproportionately to the burden of cervical lymphadenopathy.

⚠️

Clinical pearl — the 70% rule: In adults, approximately 70% of neck lumps are neoplastic and approximately 70% of neoplastic neck lumps are malignant. In children, the ratio is reversed — >80% are benign/inflammatory. Age is the single most important discriminator in the diagnostic approach.

Neck Lumps Diagnostic Model & Red Flags

Systematic Diagnostic Approach

The evaluation of a neck lump follows a three-step model: History → Examination → Investigations, with the clinical features guiding the urgency and type of referral or investigation required.

History

Duration, growth rate, pain, associated symptoms (fever, weight loss, night sweats, sore throat, ear pain, hoarseness, dysphagia), past medical history (malignancy, autoimmune disease), risk factors (smoking, alcohol, immunosuppression, EBV exposure), travel history, occupational exposure.

Examination

Site (anterior triangle, posterior triangle, midline, submandibular, supraclavicular), size, consistency (soft/firm/hard/cystic/fluctuant), mobility (mobile/fixed to skin or deep structures), tenderness, overlying skin changes, bilateral vs unilateral, associated organomegaly, oral cavity and oropharyngeal inspection, thyroid examination, cranial nerve assessment, skin check for primary malignancy.

Investigations & Referral

FBC, ESR/CRP, LDH, TFTs; ultrasound of neck (first-line imaging); FNA cytology for persistent or suspicious lesions; CT/MRI for staging; urgent 2-week referral to ENT or head and neck surgery if red flags present.

Red-Flag Features Requiring Urgent Referral

🚨

Hard, fixed, non-tender cervical lymph node >2 cm
Persistent neck lump >3 weeks without obvious infective cause, especially in patients >45 years
Supraclavicular lymphadenopathy (left = Virchow's node; right = may indicate lung/GI malignancy)
Associated hoarseness, dysphagia, odynophagia, or stridor
Unexplained weight loss, night sweats, or fever (consider lymphoma)
History of head and neck SCC, upper aerodigestive tract malignancy, or lymphoma
Significant smoking and/or alcohol history with a lateral neck mass
Rapidly progressive enlargement over days to weeks
Unilateral tonsillar enlargement with ipsilateral cervical lymphadenopathy
Skin lesion suspicious for melanoma or SCC with regional lymphadenopathy

Anatomical Differential by Site

Site	Common Differentials	Key Clinical Features
Submental	Dental infection, reactive lymph node, submental abscess, dermoid cyst	Check oral cavity and lower dentition
Submandibular	Sialadenitis (submandibular gland), lymph node, ranula	Bimanual palpation; observe for duct swelling
Parotid/pre-auricular	Parotid tumour (pleomorphic adenoma, Warthin's), mumps, reactive node	Facial nerve function; tenderness, consistency
Upper deep cervical (jugulodigastric)	Reactive node (pharyngitis, tonsillitis), tonsil SCC, lymphoma	Examine tonsils and base of tongue
Mid-deep cervical	Lymphoma, metastatic SCC, reactive node, NTM	Persistent node >3 weeks warrants investigation
Posterior triangle	Scalp/skin infection, lymphoma, metastatic nasopharyngeal carcinoma, branchial cyst	Examine scalp, nasopharynx; consider EBV
Supraclavicular	Lung/GI malignancy (left = Virchow's node), lymphoma, sarcoidosis	Almost always pathological — investigate aggressively
Midline (anterior)	Thyroid nodule/goitre, thyroglossal cyst, dermoid cyst, subhyoid bursitis	Moves with swallowing (thyroid); moves with tongue protrusion (thyroglossal)

Cervical Lymphadenopathy

Cervical lymphadenopathy is the most common cause of a neck lump across all age groups. It may be classified by aetiology into infective/inflammatory, reactive, and neoplastic categories. The clinical approach depends critically on patient age, duration, and associated features.

Aetiological Classification

Infective / Inflammatory Causes

Viral: Upper respiratory tract infection (most common overall cause), Epstein-Barr virus (infectious mononucleosis — prominent bilateral posterior cervical nodes), cytomegalovirus, HIV seroconversion, rubella, herpes simplex
Bacterial — acute: Staphylococcus aureus, Streptococcus pyogenes (Group A strep), dental abscess, cat-scratch disease (Bartonella henselae), tularemia (rare in Australia)
Bacterial — chronic/granulomatous: Tuberculous lymphadenitis (scrofula), non-tuberculous mycobacteria (NTM — M. avium complex, M. scrofulaceum — more common in paediatric populations and immunocompromised), actinomycosis, syphilis
Parasitic: Toxoplasmosis (Toxoplasma gondii — consider in young adults with isolated posterior cervical lymphadenopathy)
Fungal: Histoplasmosis (endemic in parts of northern Australia), sporotrichosis

Reactive / Autoimmune

Sarcoidosis (bilateral hilar and cervical lymphadenopathy, non-caseating granulomas)
Kikuchi-Fujimoto disease (histiocytic necrotising lymphadenitis — young women, self-limiting, associated with SLE)
Rosai-Dorfman disease (sinus histiocytosis with massive lymphadenopathy — rare)
Castlemann disease (angiofollicular lymph node hyperplasia)

Neoplastic Causes

Metastatic: Squamous cell carcinoma of the head and neck (most common — oral cavity, oropharynx, larynx, hypopharynx), thyroid carcinoma (papillary — common, follicular, medullary), nasopharyngeal carcinoma (higher incidence in Indigenous Australians and those of Southeast Asian descent), melanoma, salivary gland malignancy
Lymphoma: Hodgkin lymphoma (bimodal peak — young adults and >60 years; painless, rubbery nodes; "B symptoms"), non-Hodgkin lymphoma (older adults; more commonly extranodal at diagnosis)
Other: Kaposi sarcoma (HHV-8, immunocompromised), leukaemia, Langerhans cell histiocytosis

Consistency as a Diagnostic Clue

Consistency	Suggests	Notes
Soft, tender, mobile	Acute reactive lymphadenitis	Most common; usually self-limiting; associated URTI symptoms
Rubbery, mobile, non-tender	Lymphoma (Hodgkin or NHL)	May fluctuate in size; consider B symptoms; requires excision biopsy
Hard, fixed, non-tender	Metastatic SCC, advanced malignancy	High suspicion — urgent FNA then referral; check mucosal primary
Firm, matted, non-tender	TB lymphadenitis, NTM, sarcoidosis	Chronic course; may have draining sinus; FNA for AFB and culture
Fluctuant, warm, erythematous	Abscess (staphylococcal/streptococcal)	Incision and drainage + antibiotics; consider US to confirm
Cystic, non-tender, slowly enlarging	Branchial cleft cyst, cystic hygroma	May present after infection; US ± MRI for characterisation

Duration-Based Approach

ℹ️

<2 weeks: Likely infective/reactive. Treat underlying cause. Reassess at 2–4 weeks if not resolving.
2–6 weeks: If no infective source identified or node is atypical (hard, fixed, >2 cm, supraclavicular), perform FNA and basic bloods (FBC, ESR, LDH). Consider ultrasound.
>6 weeks and unexplained: Assume neoplastic until proven otherwise in adults. FNA ± core biopsy; urgent ENT referral. In children, consider NTM, TB, and atypical infection if not resolving.

Neck Lumps Not Due to Lymph Nodes

Thyroid Nodules and Goitre

Thyroid nodules are the most common midline neck mass, detected by palpation in 4–7% of adults and by ultrasound in up to 50%. The vast majority are benign (colloid nodules, cysts, follicular adenomas). Approximately 5–15% of clinically significant thyroid nodules harbour malignancy, most commonly papillary thyroid carcinoma.

⚠️

Thyroid nodule red flags: Rapid growth, hoarseness (recurrent laryngeal nerve involvement), hard/fixed nodule, cervical lymphadenopathy, history of head/neck irradiation, family history of medullary thyroid carcinoma or MEN2, age <20 or >60, male sex.

Investigation of Thyroid Nodules

TSH (first-line): If suppressed → radionuclide scan (hot nodules are rarely malignant). If normal or elevated → ultrasound.
Ultrasound: Characterise nodule using ACR TI-RADS or EU-TIRADS scoring. Features increasing suspicion include solid composition, hypoechogenicity, irregular margins, taller-than-wide shape, microcalcifications, and extrathyroidal extension.
FNA cytology: Indicated for TI-RADS 4 and 5 nodules >1 cm, or TI-RADS 3 nodules >2.5 cm. Results reported using the Bethesda System (Bethesda I–VI).
Serum calcitonin: Consider if medullary thyroid carcinoma suspected (family history of MEN2, elevated calcitonin on screening).

Bethesda Category	Interpretation	Risk of Malignancy	Recommended Action
I — Non-diagnostic	Insufficient cells	5–10%	Repeat FNA (± ultrasound guidance)
II — Benign	Colloid nodule, thyroiditis	0–3%	Ultrasound surveillance at 12–24 months
III — Atypia of undetermined significance	AUS/FLUS	10–30%	Repeat FNA, molecular testing, or diagnostic lobectomy
IV — Follicular neoplasm	Suspicious for follicular tumour	25–40%	Diagnostic lobectomy
V — Suspicious for malignancy	Suspicious for papillary, medullary, or metastatic	50–75%	Surgery (lobectomy ± total thyroidectomy)
VI — Malignant	Papillary, medullary, anaplastic, lymphoma	97–99%	Total thyroidectomy ± neck dissection; referral to endocrine surgery

Branchial Cleft Cysts

Branchial cleft cysts (BCCs) are congenital epithelial cysts arising from remnants of the embryological branchial apparatus. They account for approximately 2–3% of paediatric neck masses and may present at any age when secondary infection causes enlargement.

First branchial cleft cyst: Periauricular or submandibular; may be associated with the external auditory canal; classified by Work (Type I or II).
Second branchial cleft cyst (most common, ~95%): Anterior border of the sternocleidomastoid (SCM), classically at the junction of the upper and middle thirds. Smooth, fluctuant, non-tender (unless infected), transilluminates. May communicate with the tonsillar fossa via a sinus tract.
Third branchial cleft cyst: Lower neck/posterior triangle; may communicate with the piriform sinus; can present as acute suppurative thyroiditis (left-sided predominance).
Fourth branchial cleft cyst: Very rare; left-sided; low neck; also associated with recurrent acute thyroiditis.

Diagnosis: Clinical suspicion + ultrasound (well-defined cystic lesion, may have "cheerio sign" — echogenic wall with central hypoechoic region). MRI is the gold standard for defining anatomy and surgical planning.

Management: Treat active infection with antibiotics (amoxicillin-clavulanate). Definitive treatment is complete surgical excision of the cyst and any associated sinus tract, ideally electively after the infection has resolved. Recurrence rates of 3–10% following excision; higher with incomplete resection or infected state.

Pharyngeal Pouch (Zenker's Diverticulum)

A pharyngeal pouch is an outpouching of the pharyngeal mucosa through Killian's dehiscence (between the thyropharyngeus and cricopharyngeus muscles of the inferior constrictor). It is a false diverticulum (lacks a muscular layer) and occurs predominantly in elderly patients (mean age 70–80 years).

Classic triad: Dysphagia, regurgitation of undigested food, and a gurgling neck mass (left-sided, in the neck posterior to the SCM).
Other features: Halitosis, aspiration pneumonia, chronic cough, weight loss, voice change (wet voice).
Diagnosis: Barium swallow (gold standard) — demonstrates the pouch filling with contrast. Flexible nasendoscopy may show the pouch opening.
Management: Endoscopic diverticulotomy with stapling (Dohlman procedure or endoscopic laser cricopharyngeal myotomy) is first-line at most Australian tertiary centres. Open surgical diverticulectomy with cricopharyngeal myotomy is reserved for small or very large pouches unsuitable for endoscopic repair.
Complications: Aspiration pneumonia, pouch carcinoma (rare, 0.5–1%), perforation, mediastinitis (post-procedural).

ℹ️

Other non-lymph-node neck lumps to consider: Thyroglossal duct cyst (midline, moves with tongue protrusion and swallowing — Sistrunk operation is definitive treatment), lipoma (soft, compressible, often posterior triangle), carotid body tumour (pulsatile mass at carotid bifurcation — "Fontaine sign"), parotid gland tumours (pre-auricular/inferior to ear lobe), plunging ranula (submandibular space), cystic hygroma/lymphangioma (paediatric, posterior triangle, transilluminates).

Neoplastic Lymphadenopathy

Metastatic Head and Neck Squamous Cell Carcinoma

Metastatic SCC to cervical lymph nodes is the most common malignant cause of a neck lump in adults. The primary site is most often the oropharynx (tonsil, base of tongue — increasingly HPV-associated), oral cavity, larynx, or hypopharynx. In 2–5% of cases, the primary site is never identified despite exhaustive investigation (unknown primary with neck node SCC).

Nodal metastasis follows predictable drainage patterns (Levels I–VI classification), which helps localise the primary tumour.
Level I (submental/submandibular): Oral cavity primary
Level II (upper jugular — jugulodigastric): Oropharynx, oral cavity, hypopharynx
Level III (mid-jugular): Larynx, hypopharynx, thyroid
Level IV (lower jugular): Hypopharynx, thyroid, oesophagus, lung
Level V (posterior triangle): Nasopharynx, oropharynx, skin (SCC, melanoma)
Level VI (central compartment — pretracheal, paratracheal): Thyroid, larynx, oesophagus

🚨

Unknown primary: If FNA confirms SCC in a cervical node and no obvious mucosal primary is found on clinical examination, perform CT neck with contrast, PET-CT, bilateral tonsillectomy, and directed biopsies under general anaesthesia. HPV/p16 testing of the FNA specimen is essential — HPV-positive SCC has a significantly better prognosis and may arise from the oropharynx.

Lymphoma

Lymphoma accounts for approximately 25–30% of malignant neck lumps. Cervical lymphadenopathy is the most common presenting site for both Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

Hodgkin Lymphoma

Young Adult Presentation

Bimodal peak (15–35 and >60 years). Painless, rubbery, non-tender cervical lymphadenopathy (often unilateral). May have B symptoms (fever, night sweats, >10% weight loss). Alcohol-induced node pain is pathognomonic but rare. Mixed cellularity subtype more common in Indigenous Australians.

Setting: Urgent haematology referral — requires excision biopsy (not FNA) for Reed-Sternberg cells.

Non-Hodgkin Lymphoma

Older Adult Presentation

Median age 60–70 years. More commonly diffuse, multifocal, and extranodal at presentation. Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma are most common subtypes. May involve Waldeyer's ring (tonsillar NHL presents as unilateral tonsillar enlargement).

Setting: Urgent haematology referral — FNA may be sufficient for initial diagnosis; flow cytometry essential. Core biopsy preferred.

High-Risk Features

Requiring Emergent Workup

Rapidly progressive lymphadenopathy, mediastinal mass on CXR, superior vena cava obstruction, acute airway compromise, bulky disease, LDH >2× ULN, high Ki-67 — may represent aggressive NHL (Burkitt, lymphoblastic) requiring emergent chemotherapy.

Setting: Emergency haematology/oncology admission

Other Malignant Causes

Thyroid carcinoma: Papillary thyroid carcinoma frequently metastasises to cervical lymph nodes (up to 50% at diagnosis). Nodes may contain colloid and psammoma bodies; thyroglobulin staining is diagnostic. Medullary thyroid carcinoma (calcitonin-positive) may also present with cervical nodes.
Melanoma: Regional lymph node metastasis from head and neck primary (scalp melanoma has sentinel drainage to parotid and cervical nodes). Sentinel lymph node biopsy is standard staging.
Nasopharyngeal carcinoma: Higher incidence in Indigenous Australians and those of Southeast Asian, Southern Chinese, and North African descent. Often presents with bilateral upper cervical lymphadenopathy, hearing loss, and nasal obstruction. EBV-associated. Treated with chemoradiation.
Salivary gland malignancy: Mucoepidermoid carcinoma, adenoid cystic carcinoma — may metastasise to cervical nodes from parotid or submandibular gland.

Investigations

First-Line Investigations

Essential Full blood count (FBC) with differential Lymphocytosis (EBV, CLL), atypical lymphocytes (infectious mononucleosis), cytopenias (bone marrow infiltration), eosinophilia (parasitic causes). MBS item 65060.

Essential ESR and/or CRP Non-specific inflammatory markers; elevated in infection, autoimmune disease, and malignancy. MBS item 65070/65120.

Available LDH Elevated in lymphoma (tumour burden marker), also in haemolytic anaemia and tissue damage. MBS item 65090.

Available Thyroid function tests (TSH, free T4) Essential for any midline or lower anterior neck mass. TSH-suppressed nodules → radionuclide scan. MBS item 66708.

Available Serology (EBV, CMV, HIV, toxoplasma) EBV heterophile antibodies (Monospot) for suspected infectious mononucleosis; HIV serology if risk factors present or lymphadenopathy unexplained. MBS items 69306/69314/69346.

Available Mantoux / IGRA (QuantiFERON-TB Gold) For suspected TB lymphadenitis. IGRA preferred in BCG-vaccinated individuals. MBS item 69448 (IGRA).

Imaging

Essential Ultrasound — neck First-line imaging for any persistent neck lump. Differentiates solid from cystic; characterises lymph node architecture (loss of fatty hilum, rounded shape, cortical thickening >3 mm = suspicious); assesses thyroid nodules (TI-RADS scoring); guides FNA. Available at most radiology practices nationally. MBS item 55054 (US neck) + 55700 (US-guided FNA).

Referral CT neck with contrast Staging of known/suspected malignancy; assessment of deep neck spaces, extent of infection (deep neck space abscess), thyroid lesion characterisation. MBS item 56001.

Referral MRI neck Superior soft-tissue resolution; preferred for branchial cleft cysts, parapharyngeal space lesions, assessment of skull base involvement, and nasopharyngeal carcinoma. MBS item 63056.

Specialist PET-CT (18F-FDG) Staging of lymphoma and head and neck SCC; detection of unknown primary; assessment of treatment response. Not routinely requested in primary care. MBS item 61400 (authority required).

Tissue Diagnosis

Essential Fine-needle aspiration (FNA) cytology First-line tissue sampling for most persistent or suspicious neck lumps. Sensitivity 89–98% for metastatic SCC; sensitivity 65–80% for lymphoma (may be insufficient — flow cytometry recommended). Image-guided (ultrasound) FNA preferred. "Needle in clinic" for accessible lesions; otherwise radiology-guided. MBS item 30136 (FNA) + 55700 (US guidance).

Referral Core needle biopsy When FNA is non-diagnostic or lymphoma suspected (provides tissue architecture for immunohistochemistry). Usually performed under ultrasound or CT guidance by radiologist. MBS item 30071.

Specialist Excision biopsy / open biopsy Gold standard for suspected lymphoma when FNA/core biopsy non-diagnostic; for branchial cleft cysts (therapeutic); for parotid masses. Performed by ENT/head and neck surgeon under general anaesthesia. MBS item 30075.

Management & Referral Pathways

General Practice Management Algorithm

Acute Symptomatic Lymphadenopathy

If associated with URTI, pharyngitis, or dental infection — treat the underlying cause. Reassess in 2–4 weeks. If node persists, investigate.

Persistent Lymphadenopathy (2–6 weeks)

FBC, ESR/CRP, LDH, EBV/CMV serology. Arrange ultrasound neck. If ultrasound features are reassuring (normal hilum, oval shape, no cortical thickening) and patient is young with no red flags, observe a further 4–6 weeks.

Atypical or Persistent >6 Weeks

FNA cytology (image-guided). If non-diagnostic → core biopsy. Refer urgently to ENT/head and neck surgery if SCC suspected, or haematology if lymphoma suspected.

Red-Flag Present at Any Stage

Do not delay. Arrange urgent (2-week wait) referral to ENT/head and neck surgery or haematology. Perform FNA if accessible while awaiting appointment. CXR to assess for mediastinal mass or lung primary.

Referral Indications Summary

Referral Type	Indications	Timeframe
ENT / Head & Neck Surgery	Suspected head & neck SCC, unknown primary, branchial cleft cyst, pharyngeal pouch, thyroid malignancy, parotid mass, salivary gland pathology, persistent unexplained neck lump >6 weeks	Urgent (≤2 weeks) if red flags; routine 4–8 weeks otherwise
Endocrinology / Endocrine Surgery	Thyroid nodule with suspicious FNA (Bethesda IV–VI), hyperfunctioning thyroid nodule, medullary thyroid carcinoma	Urgent for Bethesda V–VI; routine for Bethesda IV
Haematology / Oncology	Suspected lymphoma, CLL, leukaemia; unexplained lymphadenopathy with systemic symptoms; elevated LDH; mediastinal mass	Urgent (≤2 weeks)
Infectious Diseases	Suspected TB lymphadenitis, NTM, chronic granulomatous lymphadenitis, immunocompromised patient with persistent lymphadenopathy	Semi-urgent (2–4 weeks)
Paediatrics	Persistent cervical lymphadenopathy >4 weeks in a child, suspected NTM, excisional biopsy for suspected lymphoma, cystic hygroma	Variable — urgent if malignancy suspected

Empirical Antibiotics for Infected Neck Lumps

Empirical antibiotics are indicated when an infective cause is suspected (acute tender lymphadenitis, branchial cleft cyst infection, neck abscess). Always consider and treat the underlying source (dental, pharyngeal, skin).

💊

Amoxicillin-Clavulanate

Augmentin® · Generic · Beta-lactam/beta-lactamase inhibitor

Adult dose 875/125 mg PO BD or 1.2 g IV TDS (if severe/systemic)

Paediatric dose 22.5/3.2 mg/kg PO BD (max 875/125 mg per dose)

Duration 7–14 days depending on clinical response

Renal adjustment eGFR 10–30: 500/125 mg BD PO; eGFR <10: 500/125 mg OD PO

PBS status ✔ PBS General Benefit

💊

Cefalexin

Keflex® · Generic · First-generation cephalosporin

Adult dose 500 mg PO QDS (skin/soft tissue source)

Paediatric dose 12.5–25 mg/kg PO QDS (max 500 mg per dose)

Duration 7–10 days

Renal adjustment eGFR 10–30: reduce dose by 50%; eGFR <10: reduce by 75%

PBS status ✔ PBS General Benefit

💊

Clindamycin

Dalacin C® · Generic · Lincosamide

Adult dose 300–450 mg PO TDS or 600 mg IV BD–TDS (severe)

Paediatric dose 10 mg/kg PO TDS (max 450 mg per dose)

Duration 7–14 days

Renal adjustment No adjustment required; dose reduction for severe hepatic impairment

PBS status ✔ PBS General Benefit

ℹ️

Note: Empirical antibiotics should not delay investigation of suspicious neck lumps. If a neck lump has red-flag features, arrange FNA/referral concurrently with empirical treatment. If the lump does not respond to 2 weeks of appropriate antibiotics, proceed to imaging and FNA regardless of age.

Special Populations

👶

Paediatrics

Cervical lymphadenopathy is extremely common in children — palpable nodes are found in 38–45% of otherwise healthy children, particularly submandibular and posterior cervical nodes.

>80% of paediatric neck lumps are infective/reactive; malignancy is rare but must be excluded in persistent cases.

Non-tuberculous mycobacteria (NTM) cervical lymphadenitis is relatively common in Australian children aged 1–5 years, particularly in Indigenous and rural populations. Presents as firm, non-tender, unilateral submandibular/pre-auricular nodes that may progress to discolouration and sinus formation.

Management of NTM: Observation alone (often self-limiting over 12–18 months) vs. surgical excision (preferred if feasible). Anti-mycobacterial therapy (clarithromycin + rifampicin) for disseminated or inoperable disease — discuss with paediatric infectious diseases.

Clarithromycin 7.5 mg/kg PO BD for NTM — PBS Authority Required for this indication.

Persistent unilateral cervical lymphadenopathy >4 weeks in a child warrants ultrasound ± FNA. Referral to paediatric ENT or paediatric oncology if malignancy suspected.

Cystic hygroma (lymphangioma) — congenital, posterior triangle, transilluminates, may cause airway compromise if large. MRI is the investigation of choice. Treatment: sclerotherapy (OK-432, bleomycin) or surgical excision.

🤰

Pregnancy

Cervical lymphadenopathy in pregnancy is usually reactive; however, the same red-flag criteria apply.

Ultrasound is safe and is the first-line imaging modality.

FNA can be performed safely during pregnancy without modification.

CT and MRI should be avoided in the first trimester if possible. MRI without gadolinium may be used from the second trimester if clinically necessary.

Lymphoma diagnosed in pregnancy requires multidisciplinary management (haematology, obstetrics, neonatology). Staging may be modified; PET-CT is contraindicated.

Thyroid nodules discovered in pregnancy — FNA can be deferred to the second trimester if not suspicious. TSH is suppressed in the first trimester (hCG-mediated) — use pregnancy-specific reference ranges.

👴

Elderly

Any new neck lump in a patient >45 years should be considered malignant until proven otherwise — lower threshold for investigation and referral.

Non-Hodgkin lymphoma and metastatic SCC are the most common malignant causes in this age group.

Pharyngeal pouch (Zenker's diverticulum) is predominantly a disease of the elderly — consider in patients with dysphagia, regurgitation, and aspiration.

Castleman disease and Rosai-Dorfman disease, while rare, tend to present in adults.

Comorbidities may complicate surgical management of neck masses; multidisciplinary discussion is essential.

🛡️

Immunocompromised

HIV-positive patients: cervical lymphadenopathy is extremely common and may be reactive (persistent generalised lymphadenopathy — PGL), infectious (TB, NTM, toxoplasmosis, CMV, fungal), or neoplastic (NHL, Kaposi sarcoma, Hodgkin lymphoma).

Transplant recipients: consider PTLD (post-transplant lymphoproliferative disorder) — EBV-driven; may present with rapidly enlarging cervical lymphadenopathy. Requires urgent biopsy and reduction of immunosuppression.

Patients on biologic immunosuppression (e.g., anti-TNF agents): increased risk of lymphoma; NTM infections; TB reactivation.

Lower threshold for biopsy in immunocompromised patients with persistent lymphadenopathy — FNA should include requests for microbiology (AFB, fungal culture) and cytology.

🫘

Renal Impairment

Patients on dialysis may develop amyloidosis (beta-2 microglobulin deposits) presenting as soft-tissue masses including in the neck.

Secondary hyperparathyroidism may cause parathyroid gland enlargement (rarely palpable).

Adjust antibiotic doses for renal function when treating infected neck lumps (see drug cards above).

Gadolinium-based MRI contrast is contraindicated in eGFR <30 (nephrogenic systemic fibrosis risk).

🫁

Hepatic Impairment

Clindamycin: dose reduction in severe hepatic impairment (close monitoring of hepatic function).

Metastatic liver disease may coexist with cervical lymphadenopathy from GI malignancy (Virchow's node).

Chronic liver disease and hepatitis C are risk factors for non-Hodgkin lymphoma.

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Australians experience a significantly higher burden of conditions causing cervical lymphadenopathy compared with the non-Indigenous population. Head and neck cancers are diagnosed at more advanced stages, infectious causes (TB, NTM, skin infections) are more prevalent, and access to specialist ENT and oncology services is more limited in remote communities.

Key Disparities and Considerations

Cancer incidence and staging

Aboriginal and Torres Strait Islander Australians are 1.7 times more likely to be diagnosed with head and neck cancers and are more likely to present with advanced-stage disease (regional or distant metastases). Five-year survival is significantly lower than for non-Indigenous Australians (AIHW, 2023).

Tuberculosis lymphadenitis

TB incidence in Aboriginal and Torres Strait Islander peoples is approximately 8 times the non-Indigenous rate, with the highest rates in the Northern Territory, Far North Queensland, and Western Australia. Cervical TB lymphadenitis (scrofula) should be actively considered in any Indigenous Australian presenting with chronic cervical lymphadenopathy, particularly if matted, fluctuant, or with sinus formation.

Non-tuberculous mycobacteria

NTM cervical lymphadenitis is more common in Indigenous children, particularly in tropical and remote regions. M. avium complex is the most frequent species. Diagnosis requires AFB culture of FNA or excised tissue (culture takes 4–8 weeks). Discuss with paediatric infectious diseases before commencing therapy.

Chronic skin and soft tissue infections

High prevalence of scabies, impetigo, and skin boils in remote Indigenous communities (particularly in children) leads to secondary reactive cervical lymphadenopathy. Recurrent or severe skin infections are a major contributor to the burden of neck lumps in these settings.

Rheumatic heart disease (RHD)

While not a direct cause of neck lumps, RHD is disproportionately prevalent in Indigenous Australians and may lead to jugular venous congestion and lymphatic stasis. This is an important comorbidity consideration in the context of neck assessment.

Remote access barriers

Specialist ENT services are concentrated in major cities. Patients in remote communities (e.g., APY Lands, Arnhem Land, Cape York) may face delays of weeks to months for specialist assessment. Telehealth ENT consultations, fly-in/fly-out specialist visits (RFDS), and point-of-care ultrasound training for remote health practitioners can reduce diagnostic delays. Ear, nose, and throat tele-otology services are expanding in the NT and WA.

Cultural safety and communication

Ensure culturally safe communication about neck lumps, particularly regarding the possibility of cancer. Use plain language and appropriate interpreters where English is not the first language. Respect obligations to family and community in shared decision-making. Engage Aboriginal Health Workers and Practitioners (AHW/Ps) in the assessment and follow-up process where available.

Recommended actions for GPs

Maintain a low threshold for investigation (ultrasound, FNA) of persistent neck lumps in Indigenous patients. Ensure TB and NTM are included in the differential for chronic cervical lymphadenopathy. Use the Royal Darwin Hospital or Cairns Hospital ENT services as regional referral hubs for northern Australia. Contact RHDAustralia (rhdaustralia.edu.au) and the NT TB Control Centre for TB advice. PBS Close the Gap CTG scripts available for eligible patients — no co-payment for medications.

Quick Reference Summary

Common Neck Lump Types — Diagnosis and Management at a Glance

Reactive lymphadenopathy

Treat underlying infection

2–4 weeks

Reassess if persists >6 weeks

Dental abscess / lymphadenitis

Amoxicillin-clavulanate + dental referral

7 days

I&D if abscess formed

Branchial cleft cyst (infected)

Amoxicillin-clavulanate or clindamycin

7–14 days

Surgical excision when infection settled

Thyroid nodule

TSH → US → FNA if indicated

—

Bethesda-guided management

Metastatic SCC (head & neck)

Urgent ENT referral + FNA

Refer ≤2 weeks

CT staging, HPV/p16 testing

Lymphoma (suspected)

Urgent haematology referral

Refer ≤2 weeks

Excision biopsy preferred; FNA + flow cytometry

TB lymphadenitis

Rifampicin + isoniazid + pyrazinamide + ethambutol (RIPE)

2 months RIPE → 4 months RI

Notify TB register; discuss with ID; AFB culture essential

Pharyngeal pouch

Endoscopic diverticulotomy

Surgical

Barium swallow diagnostic; ENT referral

📚 References

1. Australian Institute of Health and Welfare (AIHW). Cancer in Australia 2023. Canberra: AIHW; 2023. Cat. no. CAN 144.
2. Pynnonen MA, Gillespie MB, Roman B, et al. Clinical practice guideline: evaluation of the neck mass in adults. Otolaryngol Head Neck Surg. 2017;157(2_suppl):S1–S30.
3. Haynes J, Arnold KR, Aguirre-Oskins C, Chandra S. Evaluation of neck masses in adults. Am Fam Physician. 2015;91(8):562–567.
4. Royal Australian College of General Practitioners (RACGP). Guidelines for Preventive Activities in General Practice (Red Book). 9th ed. Melbourne: RACGP; 2016 (updated 2023).
5. National Health and Medical Research Council (NHMRC). Australian Clinical Practice Guidelines for the Management of Thyroid Nodules and Cancer. Endocrine Society of Australia and Australasian Association of Nuclear Medicine. Melbourne: NHMRC; 2020.
6. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.
7. Tuberculosis in Australia and New Zealand — Annual Report 2022. Communicable Diseases Intelligence. Australian Government Department of Health and Aged Care. 2023.
8. Tebruegge M, Pantazidou A, MacGregor D, et al. Non-tuberculous mycobacterial disease in children — epidemiology, diagnosis and management at a tertiary centre. PLoS One. 2014;9(1):e85748.
9. Ebrahimi A, Clark JR, Shannon CM, et al. Patterns of regional recurrence in head and neck squamous cell carcinoma: a single-institution experience. ANZ J Surg. 2014;84(11):830–835.
10. Guruprasad Y, Chauhan DS. Cervical lymphadenopathy: a diagnostic approach. Int J Otolaryngol Head Neck Surg. 2020;9:215–224.
11. Australasian Society for Infectious Diseases (ASID). Australian Therapeutic Guidelines — Antibiotic (content referenced for antibiotic recommendations). Melbourne: Therapeutic Guidelines Ltd; 2024 [used as source material, not cited directly per editorial policy].
12. Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017;27(11):1341–1346.
13. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary Report 2023. Canberra: AIHW; 2023.
14. RHDAustralia (Rheumatic Heart Disease Australia). 2020 Australian Guideline for Prevention, Diagnosis and Management of Acute Rheumatic Fever and Rheumatic Heart Disease. 3rd ed. Darwin: RHDAustralia; 2020.

for PBS scripts. Utilise ACCHS pharmacies and Remote Area Aboriginal Health Worker programs for medication supply in remote areas. Avoid initiating benzodiazepines; support holistic pain management including community-based exercise programs.

Preventive health

Promote bone health: encourage vitamin D supplementation (1000 IU daily in deficient individuals), smoking cessation support, reduction of alcohol intake, and weight-bearing exercise. MBS Item 715 health checks provide a structured opportunity to assess bone health, screen for osteoporosis risk factors, and discuss musculoskeletal health in a culturally safe context.

Quick Reference: Differential Diagnosis at a Glance

Costovertebral dysfunction

Paracetamol ± NSAID; manual therapy

2–6 weeks

Provocable on palpation; no red flags

Thoracic compression fracture

Paracetamol; ± calcitonin; DXA + osteoporosis Rx

6–12 weeks healing

Elderly; osteoporosis; acute onset

ACS (posterior MI)

Aspirin 300 mg, GTN, heparin; urgent PCI

Time-critical

ECG, troponin; CV risk factors

Aortic dissection

IV labetalol; urgent CT aortogram; surgery (Type A)

Time-critical

Tearing pain; BP differential >20 mmHg

Vertebral osteomyelitis

IV antibiotics (vancomycin + ceftriaxone initially); ID consult

6 weeks IV antibiotics

Fever, elevated CRP, IV drug use

Biliary colic / cholecystitis

Paracetamol ± morphine; lap cholecystectomy

Surgical within 72 h (cholecystitis)

RUQ/infrascapular; post-prandial; RUQ US

📚 References

1. Briggs AM, Smith AJ, Straker LM, Bragge P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. BMC Musculoskelet Disord. 2009;10:77.
2. National Health and Medical Research Council (NHMRC). Evidence-based management of acute musculoskeletal pain. Canberra: NHMRC; 2003 (updated 2020).
3. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760–765.
5. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Europ Spine J. 2018;27(1):60–75.
6. Erwin WM, Jackson PC, Homonko DA. Innervation of the human costovertebral joint: implications for clinical back pain syndromes. J Manipulative Physiol Ther. 2000;23(6):395–403.
7. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. Melbourne: RACGP; 2018 (updated 2023).
8. Hirsch JA, Singh V, Falco FJE, et al. Thoracic facet joint interventions. Pain Physician. 2016;19(4):E581–E593.
9. Erwin WM, Jackson PC. The costovertebral joint: anatomy, biomechanics, and clinical significance in thoracic back pain syndromes. J Can Chiropr Assoc. 2003;47(2):112–120.
10. Strayer RJ, Gunnerson JM, Brown LH, et al. Aortic dissection: clinical features, diagnosis, and management. Aust Crit Care. 2019;32(2):144–153.
11. Ombregt L. A system of orthopaedic medicine. 3rd edn. Edinburgh: Churchill Livingstone Elsevier; 2013. Chapter 18: Thoracic spine.
12. Lin CC, Chen KH, Li DM, et al. Characteristics and outcomes of patients presenting with thoracic back pain to the emergency department. Emerg Med Australas. 2020;32(5):805–811.

for PBS-listed medicines at participating pharmacies.

Cultural safety

Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.

Medication adherence

Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.

Specific conditions

Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.

Referral pathways

Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).

for PBS-listed medicines at participating pharmacies.

Cultural safety

Medication adherence

Specific conditions

Referral pathways

📚 References

1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).